PT Lupromax Pelumas Indonesia Tb (LMAX) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of PT Lupromax Pelumas Indonesia Tb IDR 71, price IDR 107, upside -33.8%, quality 67 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch PT Lupromax Pelumas Indonesia Tb for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
PT Lupromax Pelumas Indonesia Tbk distributes and sells lubricating oil to the retail and automotive sectors in Indonesia. The company offers additive products, including engine additives, fuel additives, and aerosol. It also provides oil products, such as gasoline engine, motorcycle, diesel engine, transmission, and industrial oils.
Show more
PT Lupromax Pelumas Indonesia Tbk distributes and sells lubricating oil to the retail and automotive sectors in Indonesia. The company offers additive products, including engine additives, fuel additives, and aerosol. It also provides oil products, such as gasoline engine, motorcycle, diesel engine, transmission, and industrial oils. The company was founded in 2017 and is based in Tangerang, Indonesia.
Stock analysis
PT Lupromax Pelumas Indonesia Tb (LMAX) currently trades at 107.00 IDR, while our model-based Fair Value estimate is 70.87 IDR, implying the stock looks roughly 51.0% overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 92.15 IDR per share, and 3 of the 20 models we run sit above the 107.00 IDR price.
Bear case: the Multiples group reads lowest at 24.98 IDR, and 17 of the 20 models stay below the price. Evidence for this calculation is low.
Scenario range: 62.72 IDR (bear) to 82.27 IDR (bull), the price of 107.00 IDR sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 67/100 (solid quality), in the Energy sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
PT Lupromax Pelumas Indonesia Tb reported revenue of 78.3B IDR in FY2024 versus 37.7B IDR in FY2022, a compound +44.1%/yr. Reported net income was 955M IDR in FY2024, compounding −39.2%/yr from FY2022.
Key figures
Market cap 69.6B IDR (≈ $3.9M) · P/S ratio 1.06 · Net margin 1.2% · Return on equity 1.4% · Return on assets (EBIT) 6.9% · Operating margin 3.1% · Revenue (TTM) 67.7B IDR · Revenue growth (YoY) −12.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 45 out of 100 (low confidence).
What moves the price
The share trades about 53% below its 52-week high and 55% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Energy peers we cover trades at −61% fair-value upside, at −34%, LMAX screens cheaper than that median.
Fair Value models
Bear 62.72 IDRFair Value 70.87 IDRBull 82.27 IDR
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.77/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: only 3 usable fiscal years, at least 4 required
Compare PT Lupromax Pelumas Indonesia Tb with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Oil & Gas Refining & Marketing · 110 stocks
Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score67 · Top 25%
Fair Value upside−34% · Below median
Profitability
Return on equity (TTM)1% · Bottom 25%
Return on assets1% · Bottom 25%
Net margin (TTM)1% · Below median
Operating margin (TTM)3% · Below median
Growth and dividend
Revenue growth−12% · Bottom 25%
Balance sheet
Debt / equity0.03× · Lowest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 18
FUTURE (revenue growth)0· sector 15
PAST (return on equity)6· sector 35
HEALTH (low debt)99· sector 81
DIVIDEND (yield)0· sector 53
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "PT Lupromax Pelumas Indonesia Tb Fair Value". https://www.fairvalue-calculator.com/stock/LMAX
Frequently asked questions
Is PT Lupromax Pelumas Indonesia Tb (LMAX) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 70.87 IDR versus a price of 107.00 IDR, about −34% upside (overvalued).
What is the fair value of LMAX?
Our model-based fair value for PT Lupromax Pelumas Indonesia Tb is 70.87 IDR (as of Sep 24, 2026), built from audited fundamentals. The current price: 107.00 IDR.
What is the quality score of LMAX?
PT Lupromax Pelumas Indonesia Tb has a Quality Score of 67/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for PT Lupromax Pelumas Indonesia Tb (LMAX)?
Our model-based price target is the fair value of 70.87 IDR (as of Sep 24, 2026) from 20 valuation models. Cautious scenario 62.72 IDR, optimistic scenario 82.27 IDR. It is a calculation from audited fundamentals, not an analyst target.
What is the PT Lupromax Pelumas Indonesia Tb stock forecast for 2026?
Our models put fair value at 70.87 IDR, about −34% upside versus a price of 107.00 IDR (overvalued). Cautious scenario 62.72 IDR, optimistic scenario 82.27 IDR. The calculation is refreshed regularly with new filings.
What is the revenue of PT Lupromax Pelumas Indonesia Tb (LMAX)?
PT Lupromax Pelumas Indonesia Tb reported trailing-twelve-month revenue of about 67.7B IDR (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of PT Lupromax Pelumas Indonesia Tb (LMAX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For PT Lupromax Pelumas Indonesia Tb it is 70.87 IDR per share (as of Sep 24, 2026), against a price of 107.00 IDR. It is the blended result of 20 valuation models (cash flow, earnings, asset, dividend).
Is PT Lupromax Pelumas Indonesia Tb stock overvalued or undervalued in 2026?
As of Sep 24, 2026, LMAX trades above its calculated fair value: price 107.00 IDR, fair value 70.87 IDR, a gap of about −34% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LMAX?
No. The price is what the market pays today (107.00 IDR); the fair value is what the company's own numbers justify (70.87 IDR). For PT Lupromax Pelumas Indonesia Tb the two are 36.13 IDR per share apart. That gap is exactly why we show both numbers side by side.
How much is PT Lupromax Pelumas Indonesia Tb worth?
The market values PT Lupromax Pelumas Indonesia Tb at about 69.6B IDR (market capitalisation, as of Sep 24, 2026). Per share that is 107.00 IDR; our models calculate a fair value of 70.87 IDR per share.
What do the bullish and bearish scenarios say about LMAX?
Our models span a range for PT Lupromax Pelumas Indonesia Tb: cautious scenario 62.72 IDR, base 70.87 IDR, optimistic 82.27 IDR per share (as of Sep 24, 2026, price 107.00 IDR). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of PT Lupromax Pelumas Indonesia Tb (LMAX)?
Balance-sheet figures for PT Lupromax Pelumas Indonesia Tb (as of Sep 24, 2026): return on equity 1.4%, debt of 0.03 per unit of equity. They feed the Quality Score of 67/100, which measures business quality independently of the share price.
How far is LMAX from its 52-week high?
PT Lupromax Pelumas Indonesia Tb trades at 107.00 IDR, about 53% below its 52-week high of 226.00 IDR and 55% above the low of 69.00 IDR (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 70.87 IDR is for.
Which stocks are comparable to PT Lupromax Pelumas Indonesia Tb?
From the same area (Energy) we also value Reliance Industries Limited, Valero Energy Corporation, Marathon Petroleum Corporation, Phillips 66, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is PT Lupromax Pelumas Indonesia Tb stock attractive at the current price?
The data as of Sep 24, 2026: price 107.00 IDR, calculated fair value 70.87 IDR (−34%), Quality Score 67/100, from 20 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LMAX calculated?
We run PT Lupromax Pelumas Indonesia Tb through 20 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 70.87 IDR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. PT Lupromax Pelumas Indonesia Tb itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of PT Lupromax Pelumas Indonesia Tb (LMAX)?
The closing price on Sep 24, 2026 was 107.00 IDR. Our model-based fair value is 70.87 IDR, about −34% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with PT Lupromax Pelumas Indonesia Tb right now?
The price sits above even our optimistic bull case (82.27 IDR). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (67/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of PT Lupromax Pelumas Indonesia Tb
How large is the market capitalisation of PT Lupromax Pelumas Indonesia Tb (LMAX)?
The market capitalisation of PT Lupromax Pelumas Indonesia Tb is 69.6B IDR (≈ $3.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of PT Lupromax Pelumas Indonesia Tb (LMAX)?
The price-to-sales ratio of PT Lupromax Pelumas Indonesia Tb is 1.06 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of PT Lupromax Pelumas Indonesia Tb (LMAX)?
The net margin of PT Lupromax Pelumas Indonesia Tb is 1.2% (fiscal year 2024). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of PT Lupromax Pelumas Indonesia Tb (LMAX)?
The return on equity (ROE) of PT Lupromax Pelumas Indonesia Tb is 1.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of PT Lupromax Pelumas Indonesia Tb (LMAX)?
On an EBIT basis the return on assets of PT Lupromax Pelumas Indonesia Tb is 6.9% (avg 3y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of PT Lupromax Pelumas Indonesia Tb (LMAX)?
The operating margin of PT Lupromax Pelumas Indonesia Tb is 3.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at PT Lupromax Pelumas Indonesia Tb (LMAX)?
Revenue at PT Lupromax Pelumas Indonesia Tb is growing −12.1% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at PT Lupromax Pelumas Indonesia Tb (LMAX)?
Earnings per share at PT Lupromax Pelumas Indonesia Tb are growing −46.3% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch PT Lupromax Pelumas Indonesia Tb in the live analysis
One click puts PT Lupromax Pelumas Indonesia Tb on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
